Authors

Naval Daver, MD, The University of Texas MD Anderson Cancer Center

Naval Daver, MD, University of Texas MD Anderson Cancer Center

Naval G. Daver, MD

Latest:

Dr Daver on the Potential Role for Menin Inhibitors in Frontline AML

Naval G. Daver, MD, discusses the potential role for menin inhibitors in the frontline treatment of patients with acute myeloid leukemia.

Naval G. Daver, MD, MD Anderson Cancer Center

Latest:

Dr Daver on the Potential Role of MRD Assessment in AML Treatment

Naval G. Daver, MD, discusses the potential role of minimal residual disease assessments in acute myeloid leukemia.

Naval G. Daver, MD The University of Texas MD Anderson Cancer Center

Naveed Saleh, MD, MS

Latest:

Navigating Treatment Options for Patients With Early-Stage Breast Cancer

Genetic advances have helped elucidate the heterogenous nature of breast cancer, however optimal strategies for patients with early-stage disease still need to be ironed out.

Naveed Zafar Janjua, MBBS, MSc, DrPH

Latest:

Dr. Naveed Zafar Janjua on Impact of Hepatitis C Treatment Timing on HCC Risk

Naveed Zafar Janjua, MBBS, MSc, DrPH, senior scientist, clinical prevention services, BC Centre for Disease Control and clinical associate professor, School of Population and Public Health, University of British Columbia, discusses the findings from the British Columbia hepatitis testers cohort, which looked at the impact of hepatitis infection on long term risk of hepatocellular carcinoma (HCC).

Naveen Pemmaraju, MD

Latest:

First-Line Tagraxofusp in BPDCN: Subgroup Analyses by Age and Fitness

Naveen Pemmaraju, MD, reviews subgroup analyses of tagraxofusp as first-line therapy in BPDCN, highlighting durable responses and successful transplant bridging across age and fitness groups

Navesh K. Sharma, DO, PhD

Latest:

Dr. Sharma on Tolerability of SIRT in Patients With CRC

Dr. Navesh K. Sharma, associate professor of Radiology in the Division of Radiology and Oncology at Penn State Hershey Medical Center and section chief of Radiation Oncology at the Penn State Health St. Joseph Cancer Center, discusses the safety profile of selective internal radiation therapy (SIRT) when added to chemotherapy for patients with colorectal cancer (CRC) that has metastasized to the liver.

Neal D. Shore, MD

Latest:

ARPI-Based Combination Regimens – CONTACT-02 (Cabozantinib plus atezolizumab)

Panelists discuss how the CONTACT-02 trial highlights the potential of cabozantinib combined with atezolizumab in improving treatment outcomes for patients with advanced cancer.

Neal D. Shore, MD, Ca

Neal D. Shore, MD, FACS

Latest:

Understanding Efficacy, Safety, and PSA Kinetics of Apalutamide Plus ADT in Patients With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Sponsored Content: Neal Shore, MD, FACS reviews new data on the TITAN trial of apalutamide in patients with mCSPC.

Neal D. Shore, MD, FACS, Carolina Urologic Research Center

Latest:

Rapid Readouts: Phase 3 HERO Trial

Neal Dave

Latest:

The Role of Positive Quality Interventions

Neal Dave, PharmD, Texas Oncology, discusses the role of positive quality interventions (PQI).

Neal E. Ready, MD, PhD, Duke University Medical Center

Latest:

Dr. Ready on Leveraging Nivolumab/Ipilimumab Plus Chemotherapy in NSCLC

Neal Edward Ready, MD, PhD, discusses factors to consider when deciding when the use the regimen of nivolumab and ipilimumab plus chemotherapy in metastatic non–small cell lung cancer.

Neal J. Weinreb, MD

Latest:

Dr. Weinreb on the Different Roles in a Gaucher Diagnosis

Dr. Neal Weinreb, from University Research Foundation for Lysosomal Storage Diseases, on the Different Roles in a Gaucher Diagnosis

Neal P. Christiansen, MD

Latest:

Treatment Patterns of Metastatic Triple-Negative Breast Cancer in US Community Practice Settings

First-line treatment patterns for metastatic triple-negative breast cancer are diverse, reflecting a lack of consensus and an unmet need for standardized therapy.

Neal Shore, MD, FACS

Neal Shore, MD, FACS, is the medical director for the Carolina Urologic Research Center

Latest:

Ongoing ADT Use and Research Emphasizes the Importance of Shared Decision-Making in Prostate Cancer Care: With Neal Shore, MD, FACS

Dr Shore discusses the use of ADT in patients with prostate cancer, as well as toxicities and quality-of-life complications associated with these agents.

Neal Shore, MD, FACS, Carolina Urologic Research Center

Neal Young, MD

Latest:

Dr. Young on Eltrombopag Added to Immunosuppression for Patients With Aplastic Anemia

Neal Young, MD, senior investigator, Cell Biology Section, National Heart, Lung, and Blood Institute, National Institute of Health, discusses a study that examined the efficacy of eltrombopag when added to standard immunosuppression for patients with aplastic anemia.